Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI) 2Q26

About this update from Neonc Technologies Holdings, Inc.

Dallas, Texas--(Newsfile Corp. - August 13, 2026) - NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI). Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI). 2Q26 meaningfully improves the clinical setup for NTHI, with NEO100 delivering a positive Phase 2a readout and NEO212 gaining regulatory clarity. NEO100 met its primary endpoint with six-month PFS of 48.9% by RANO 2.0 using Kaplan-Meier estimation versus a pre-specified 20% benchmark (p=0.0047), while median OS reached 26.09 months and no major toxicities were reported. We view the survival signal as the more important read through, with management citing 6-9 months for current salvage therapy in recurrent brain cancer, although confirmation in a randomized study remains the next test. The readout moves NEO100 into a potential registrational program, with the Company intending to request a Type B FDA meeting. Financial results are secondary, with R&D increasing to $2.6M vs. $0.7M y/y. To view the full announcement, including downloadable images, bios, and more, click here . Key Takeaways: Click image above to view full announcement. About Stonegate Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA) provides a full spectrum of investment banking services for public and private companies. Contacts: Stonegate Capital Partners (214) 987-4121 [email protected] Source: Stonegate, Inc. To view the source version of this press release, please visit https://www.newsfilecorp.com/release/309582

View stock analysis, news, and events for Neonc Technologies Holdings, Inc.